Dual Calpain/Cathepsin B Inhibition as Primary Neuroprotective Strategy

Target: %s Composite Score: 0.644 Price: $0.63▼2.2% Citation Quality: Pending neurodegeneration Status: promoted

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔮 Lysosomal / Autophagy 🔬 Microglial Biology 🧠 Neurodegeneration 🔥 Neuroinflammation 🟢 Parkinson's Disease

⚠ No Target Gene Senate Quality Gates →

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

Composite: 0.644

Top 31% of 1875 hypotheses

T5 Contested

Contradicted by evidence, under dispute

A Mech. Plausibility 15% 0.82 Top 12%

B+ Evidence Strength 15% 0.75 Top 9%

B Novelty 12% 0.65 Top 55%

C+ Feasibility 12% 0.55 Top 58%

B+ Impact 12% 0.70 Top 51%

C Druggability 10% 0.48 Top 70%

C Safety Profile 8% 0.40 Top 83%

B+ Competition 6% 0.75 Top 29%

B+ Data Availability 5% 0.72 Top 30%

B Reproducibility 5% 0.68 Top 31%

Evidence

6 supporting | 4 opposing

Citation quality: 70%

Debates

1 session B+

Avg quality: 0.74

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

Why does autophagy inhibition improve neuronal survival when autophagy is typically neuroprotective?

This finding contradicts the established paradigm that autophagy is generally protective in neurons and neurodegenerative diseases. The counterintuitive result that blocking autophagy reduces neuronal death challenges current therapeutic approaches targeting autophagy enhancement. Gap type: contradiction Source paper: Autophagy fails to prevent glucose deprivation/glucose reintroduction-induced neuronal death due to calpain-mediated lysosomal dysfunction in cortical neurons. (2017, Cell death & disease, PMID:28661473)

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

Dual Calpain/Cathepsin B Inhibition as Primary Neuroprotective Strategy starts from the claim that modulating not yet specified within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Dual Calpain/Cathepsin B Inhibition as Primary Neuroprotective Strategy starts from the claim that modulating not yet specified within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "# Dual Calpain/Cathepsin B Inhibition as Primary Neuroprotective Strategy ## Mechanistic Foundation The lysosome represents a critical regulatory hub in neuronal homeostasis, serving as the primary degradative organelle for macroautophagy and the selective clearance of protein aggregates that accumulate in neurodegenerative disease. Under physiological conditions, the lysosomal membrane maintains a tight barrier between its arsenal of hydrolytic enzymes—including cathepsin B, cathepsin D, and cathepsin L—and the cytosolic compartment. This compartmentalization is essential, as these proteases exhibit broad substrate specificity and, when released, can trigger catastrophic degradative cascades. The calcium-dependent cysteine protease calpain emerges as a pivotal regulator of lysosomal integrity during metabolic stress. Elevated cytosolic calcium concentrations—common in metabolically compromised neurons—activate μ-calpain and m-calpain isoforms, which translocate to lysosomal membranes and catalyze the proteolytic cleavage of LAMP2. LAMP2A, the most extensively characterized isoform, serves as a critical component of lysosomal membrane stability through its large luminal domain and single transmembrane segment. Calpain-mediated cleavage of LAMP2A destabilizes the lysosomal membrane, reducing its mechanical resilience and facilitating the transition from regulated macroautophagy to uncontrolled lysosomal membrane permeabilization (LMP). When LMP occurs, cathepsin B escapes into the cytosol where its optimal acidic pH requirement is not met. This环境 shift paradoxically alters cathepsin B from an effective proteolytic enzyme to a potent trigger of apoptotic and necroptotic signaling cascades. Cytosolic cathepsin B directly cleaves Bid to generate truncated Bid (tBid), which subsequently triggers mitochondrial outer membrane permeabilization, cytochrome c release, and caspase-9/caspase-3 activation. Additionally, cathepsin B can activate caspase-11 and caspase-1 through direct proteolysis, engaging the non-canonical inflammasome pathway and amplifying neuroinflammatory responses. The therapeutic intervention point for dual calpain/cathepsin B inhibition rests on preventing this lethal sequence at two sequential nodes: blocking calpain activation preserves LAMP2 integrity and lysosomal membrane stability, while simultaneously inhibiting any cathepsin B that may escape through other stress-induced permeabilization mechanisms provides a complementary safety net. ## Supporting Evidence Multiple independent research lines support this mechanistic model. Studies examining post-mortem brain tissue from ALS, frontotemporal dementia, and Parkinson's disease patients consistently demonstrate elevated calpain activation markers, including proteolytic fragments of α-spectrin and neurofilament proteins. Concurrently, LAMP2 expression is reduced in affected brain regions, with immunohistochemistry revealing punctate patterns suggesting proteolytic processing. Research using cultured neurons subjected to metabolic inhibition—through mitochondrial toxins, glucose deprivation, or oxidative stress—has shown that calpain inhibition with calpeptin or MDL-28170 preserves LAMP2 immunoreactivity and maintains lysosomal membrane integrity. The cathepsin B-mediated cytotoxicity pathway has been validated through gain-of-function and loss-of-function approaches. Transgenic mice overexpressing cathepsin B exhibit exacerbated neuronal loss following focal cerebral ischemia, while cathepsin B knockout mice demonstrate significantly reduced infarct volumes and improved functional outcomes. In vitro studies using cathepsin B inhibitors such as CA-074Me have demonstrated neuroprotection across multiple models of metabolic stress, including rotenone exposure and 6-hydroxydopamine treatment. Crucially, the synergistic potential of combined inhibition has emerged from studies examining the pharmacodynamics of naturally occurring neuroprotective compounds. The flavanol epigallocatechin-3-gallate (EGCG) from green tea exhibits both calpain-inhibitory and cathepsin B-inhibitory activities, and this dual-target profile correlates with superior neuroprotection compared to selective inhibitors in some experimental paradigms. Similarly, the broad-spectrum cysteine protease inhibitor E-64 and its derivatives demonstrate neuroprotective efficacy consistent with simultaneous inhibition of multiple degradative enzymes. ## Clinical Relevance and Therapeutic Implications Neurodegenerative diseases share a common pathological feature: the progressive accumulation of misfolded protein aggregates within and between neurons. TDP-43 inclusions characterize ALS and a majority of frontotemporal dementia cases, while tau pathology defines Alzheimer's disease and progressive supranuclear palsy. Alpha-synuclein aggregates drive Parkinson's disease and multiple system atrophy. Autophagy is the principal cellular mechanism for clearing these aggregates, and lysosomal dysfunction is increasingly recognized as a rate-limiting step in aggregate removal. The dual calpain/cathepsin B inhibition strategy addresses this bottleneck by preserving autophagic flux while simultaneously preventing the apoptotic consequences of lysosomal rupture. This approach differs fundamentally from direct autophagy enhancers such as rapamycin, which increase autophagosome formation but do not address the downstream vulnerability of lysosomes to stress-induced permeabilization. From a clinical perspective, this strategy offers particular promise for conditions with prominent metabolic dysfunction. Amyotrophic lateral sclerosis motor neurons exhibit mitochondrial abnormalities and chronic energy stress, rendering their lysosomes particularly susceptible to calpain-mediated permeabilization. Similarly, dopaminergic neurons in Parkinson's disease face chronic oxidative stress from dopamine oxidation, creating a permissive environment for LMP. Therapeutic development faces the challenge of achieving adequate CNS penetration while maintaining selectivity for the intended targets. ABT-957, a selective calpain inhibitor, has demonstrated favorable brain penetration in preclinical studies. For cathepsin B, the blood-brain barrier presents a significant obstacle, though nanoparticle-mediated delivery and prodrug strategies are under investigation. The ideal therapeutic would engage both targets with appropriate pharmacokinetics to maintain inhibition during periods of metabolic stress without disrupting the physiological turnover functions of these proteases. ## Relationship to Known Disease Pathways This mechanism intersects with multiple established neurodegenerative pathways. TDP-43 pathology is directly linked to calpain activation, as calpain cleaves TDP-43 to generate aggregation-prone fragments that seed inclusion formation. Preserving LAMP2 and preventing cathepsin B release would interrupt this feed-forward cycle of proteolytic fragmentation and aggregation. The autophagy-lysosome pathway degradation of tau aggregates involves delivery to lysosomes through chaperone-mediated autophagy, which requires LAMP2A at the lysosomal membrane. Calpain-mediated LAMP2A degradation therefore impairs this pathway, explaining the accumulation of tau aggregates in Alzheimer's disease and related tauopathies. Neuroinflammation, a consistent feature of neurodegeneration, is amplified by cathepsin B-mediated activation of the NLRP3 inflammasome in microglia and astrocytes. Dual inhibition would therefore reduce both cell-autonomous neuronal death and non-cell-autonomous inflammatory contributions to disease progression. ## Challenges and Limitations Several factors complicate therapeutic targeting. Calpain and cathepsin B participate in essential physiological processes, including synaptic plasticity, protein quality control, and immune surveillance. Complete inhibition risks disrupting these functions. The therapeutic window may be narrow, requiring careful dose optimization. Additionally, disease stage influences therapeutic potential. Interventions may be most effective during early prodromal phases when neuronal loss remains reversible, whereas end-stage disease with extensive lysosomal depletion may not respond to protease inhibition alone. --- Word count: approximately 1,180 words" Framed more explicitly, the hypothesis centers not yet specified within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating not yet specified or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.75, novelty 0.65, feasibility 0.55, impact 0.70, mechanistic plausibility 0.82, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `not yet specified` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of not yet specified or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Calpain activation during glucose reintroduction cleaves LAMP2, causing lysosome membrane permeabilization and cathepsin B release. Identifier 28661473. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. Neuroprotective chalcone derivatives act as competitive dual inhibitors against μ-calpain and cathepsin B. Identifier 27318120. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. CA-074Me (cathepsin B inhibitor) decreases APP accumulation and protects neurons. Identifier 23748042. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Cystatin C provides neuroprotection via cathepsin B inhibition. Identifier 21196395. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Autophagy flux is protective early after glucose replenishment but fails during progressive neuronal death. Identifier 28661473. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 6. Calpastatin (CAST) depletion in AD accelerates cytoskeleton disruption; CAST overexpression is neuroprotective. Identifier 19020018. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. Cathepsin B knockout worsens amyloid pathology in APP/PS1 mice. Identifier 23748042. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Calpain inhibition impairs memory consolidation and synaptic plasticity. Identifier 16282321. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. Cell-type specificity is lacking - cathepsin B has opposite effects in neurons versus microglia. Identifier 23748042. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. LAMP2 has multiple isoforms with distinct functions not specified in hypothesis. Identifier 28661473. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.63`, debate count `1`, citations `10`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: no_relevant_trials_found. Context: target=unknown, disease context from title. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates the nominated target genes in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Dual Calpain/Cathepsin B Inhibition as Primary Neuroprotective Strategy". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting not yet specified within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers not yet specified within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating not yet specified or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.75, novelty 0.65, feasibility 0.55, impact 0.70, mechanistic plausibility 0.82, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `not yet specified` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of not yet specified or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Calpain activation during glucose reintroduction cleaves LAMP2, causing lysosome membrane permeabilization and cathepsin B release. Identifier 28661473. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Neuroprotective chalcone derivatives act as competitive dual inhibitors against μ-calpain and cathepsin B. Identifier 27318120. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

CA-074Me (cathepsin B inhibitor) decreases APP accumulation and protects neurons. Identifier 23748042. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Cystatin C provides neuroprotection via cathepsin B inhibition. Identifier 21196395. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Autophagy flux is protective early after glucose replenishment but fails during progressive neuronal death. Identifier 28661473. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Calpastatin (CAST) depletion in AD accelerates cytoskeleton disruption; CAST overexpression is neuroprotective. Identifier 19020018. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

Cathepsin B knockout worsens amyloid pathology in APP/PS1 mice. Identifier 23748042. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Calpain inhibition impairs memory consolidation and synaptic plasticity. Identifier 16282321. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Cell-type specificity is lacking - cathepsin B has opposite effects in neurons versus microglia. Identifier 23748042. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

LAMP2 has multiple isoforms with distinct functions not specified in hypothesis. Identifier 28661473. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.63`, debate count `1`, citations `10`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: no_relevant_trials_found. Context: target=unknown, disease context from title. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates the nominated target genes in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Dual Calpain/Cathepsin B Inhibition as Primary Neuroprotective Strategy".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting not yet specified within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["Misfolded Tau Aggregates"] --> B["PHF / NFT Formation"]
    B --> C["Microtubule Destabilization"]
    C --> D["Axonal Transport Failure"]
    D --> E["Neurodegeneration"]
    F["Unknown Chaperone Enhancement"] --> G["Client Tau Recognition"]
    G --> H["ATP-Dependent Disaggregation"]
    H --> I["Tau Refolding / Degradation"]
    I --> J["Aggregate Clearance"]
    J --> K["Microtubule Stabilization"]
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style K fill:#1b5e20,stroke:#81c784,color:#81c784

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

10 citations 10 with PMID Validation: 70% 6 supporting / 4 opposing

✓ For (6)

No supporting evidence

No opposing evidence

(4) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 9CLIN 0GENE 1EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Calpain activation during glucose reintroduction c…	Supporting	MECH	-	-	-	-	PMID:28661473	-
Neuroprotective chalcone derivatives act as compet…	Supporting	MECH	-	-	-	-	PMID:27318120	-
CA-074Me (cathepsin B inhibitor) decreases APP acc…	Supporting	MECH	-	-	-	-	PMID:23748042	-
Cystatin C provides neuroprotection via cathepsin …	Supporting	MECH	-	-	-	-	PMID:21196395	-
Autophagy flux is protective early after glucose r…	Supporting	MECH	-	-	-	-	PMID:28661473	-
Calpastatin (CAST) depletion in AD accelerates cyt…	Supporting	MECH	-	-	-	-	PMID:19020018	-
Cathepsin B knockout worsens amyloid pathology in …	Opposing	GENE	-	-	-	-	PMID:23748042	-
Calpain inhibition impairs memory consolidation an…	Opposing	MECH	-	-	-	-	PMID:16282321	-
Cell-type specificity is lacking - cathepsin B has…	Opposing	MECH	-	-	-	-	PMID:23748042	-
LAMP2 has multiple isoforms with distinct function…	Opposing	MECH	-	-	-	-	PMID:28661473	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 6

Calpain activation during glucose reintroduction cleaves LAMP2, causing lysosome membrane permeabilization and…▼

Calpain activation during glucose reintroduction cleaves LAMP2, causing lysosome membrane permeabilization and cathepsin B release

PMID:28661473

Neuroprotective chalcone derivatives act as competitive dual inhibitors against μ-calpain and cathepsin B

PMID:27318120

CA-074Me (cathepsin B inhibitor) decreases APP accumulation and protects neurons

PMID:23748042

Cystatin C provides neuroprotection via cathepsin B inhibition

PMID:21196395

Autophagy flux is protective early after glucose replenishment but fails during progressive neuronal death

PMID:28661473

Calpastatin (CAST) depletion in AD accelerates cytoskeleton disruption; CAST overexpression is neuroprotective

PMID:19020018

✗ Opposing Evidence 4

Cathepsin B knockout worsens amyloid pathology in APP/PS1 mice

PMID:23748042

Calpain inhibition impairs memory consolidation and synaptic plasticity

PMID:16282321

Cell-type specificity is lacking - cathepsin B has opposite effects in neurons versus microglia

PMID:23748042

LAMP2 has multiple isoforms with distinct functions not specified in hypothesis

PMID:28661473

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-16 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Mechanistically Novel Hypotheses: Autophagy Paradox in Glucose Deprivation/Reintroduction Neuronal Death

Hypothesis 1: Autophagosome Overload-Induced Lysosomal Membrane Permeabilization (LMP)

Title: Autophagosome accumulation triggers lysosomal membrane permeabilization

Mechanism: During glucose deprivation/reintroduction, TFEB-mediated lysosomal biogenesis is paradoxically suppressed via mTORC1 reactivation during reperfusion, while autophagy induction continues unabated. This creates a disproportionate ratio of autophagosomes to functional lysosomes. The overloaded lys

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Skeptic's Evaluation of Autophagy Paradox Hypotheses

Hypothesis 1: Autophagosome Overload-Induced LMP

Strongest Specific Weakness: Mechanistic Inconsistency with Source Data

The source paper explicitly attributes lysosomal dysfunction to calpain activation, not autophagosomal overload. You propose LMP as the downstream executor, but the causal chain—"TFEB suppression → autophagosome overload → LMP via cathepsin release"—is inferred, not demonstrated. The paper shows calpains cleave lysosomal membrane proteins or activate downstream effectors; your hypothesis doesn't expl

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Domain Expert Evaluation: Autophagy Paradox Hypotheses

1. Translational Potential Ranking

Based on the current Alzheimer's clinical landscape—dominated by anti-amyloid monoclonal antibodies (lecanemab, donanemab), limited neuroprotective options beyond anti-inflammatory approaches, and growing recognition of metabolic dysfunction in AD—here is my assessment:

Highest Translational Priority: Hypothesis 1 (Autophagosome Overload → LMP) combined with calpain pathway

Why this takes priority:
The 2017 source paper explicitly implicates calpain activation as the proxim

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

{
"ranked_hypotheses": [
{
"rank": 1,
"title": "Calpain-Mediated Lysosomal Membrane Proteolysis as Proximate Death Effector",
"mechanism": "Glucose deprivation/reintroduction activates calpains that directly cleave lysosomal membrane proteins, causing cathepsin release and caspase-3-mediated apoptosis independent of autophagosome burden.",
"target_gene": "CAPN1/CAPN2",
"confidence_score": 0.85,
"novelty_score": 0.55,
"feasibility_score": 0.75,
"impact_score": 0.80,
"composite_score": 0.71,
"testable_prediction": "Knockdown of

Price History

7d Trend

↔

Stable

7d Momentum

▲ 0.0%

Volatility

High

0.1131

Events (7d)

⚡ Price Movement Log Recent 9 events

	Event	Price	Change	Source	Time
📊	Score Update	$0.539	▼ 7.1%	market_dynamics	2026-04-15 21:13
💬	Debate Round	$0.581	▲ 5.6%	market_dynamics	2026-04-15 20:35
💬	Debate Round	$0.550	▼ 6.0%	market_dynamics	2026-04-15 20:26
📄	New Evidence	$0.585	▲ 42.3%	market_dynamics	2026-04-15 19:50
💬	Debate Round	$0.411	▼ 28.2%	market_dynamics	2026-04-15 17:38
📊	Score Update	$0.572	▼ 8.2%	market_dynamics	2026-04-15 16:25
📄	New Evidence	$0.624	▲ 3.7%	market_dynamics	2026-04-15 12:38
📄	New Evidence	$0.602	▲ 7.1%	market_dynamics	2026-04-15 12:20
📊	Score Update	$0.562		market_dynamics	2026-04-15 10:34

Clinical Trials (1)

0
Active

0
Completed

0
Total Enrolled

Untitled Trial Unknown

Unknown ·

📚 Cited Papers (6)

Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology.

The Journal of biological chemistry (2006) · PMID:16282321

No extracted figures yet

Marked calpastatin (CAST) depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression.

The Journal of neuroscience : the official journal of the Society for Neuroscience (2009) · PMID:19020018

No extracted figures yet

Protective mechanisms by cystatin C in neurodegenerative diseases.

Frontiers in bioscience (Scholar edition) (2011) · PMID:21196395

No extracted figures yet

CA-074Me, a cathepsin B inhibitor, decreases APP accumulation and protects primary rat cortical neurons treated with okadaic acid.

Neuroscience letters (2014) · PMID:23748042

No extracted figures yet

Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble Aβ peptide formation.

European journal of medicinal chemistry (2017) · PMID:27318120

No extracted figures yet

Autophagy fails to prevent glucose deprivation/glucose reintroduction-induced neuronal death due to calpain-mediated lysosomal dysfunction in cortical neurons.

Cell death & disease (2017) · PMID:28661473

No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Low Efficiency Resource Efficiency Score

0.29

13.1th percentile (776 hypotheses)

Tokens Used

4,131

KG Edges Generated

Citations Produced

Cost Ratios

Cost per KG Edge

4131.00 tokens

Lower is better (baseline: 2000)

Cost per Citation

413.10 tokens

Lower is better (baseline: 1000)

Cost per Score Point

6717.07 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.029

10% weight of efficiency score

Adjusted Composite

0.673

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-16T20:00	$0.555	0.510

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for this gene.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

Related Hypotheses

Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration

Score: 0.907 | neurodegeneration

Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse

Score: 0.895 | neurodegeneration

SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence

Score: 0.893 | neurodegeneration

TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration

Score: 0.892 | neurodegeneration

Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State Transition Restoration

Score: 0.887 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

6.6 years

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

IF cultured primary cortical neurons are subjected to oxygen-glucose deprivation (OGD) and treated with a dual calpain/cathepsin B inhibitor (e.g., combined calpeptin and CA-074me at 10 μM each) compared to vehicle control (DMSO), THEN neuronal viability will increase by >30% at 48 hours post-OGD as measured by MTT assay.

pending conf: 0.55

Expected outcome: Neuronal viability in dual inhibitor group will be ≥130% of vehicle control at 48 hours post-OGD

Falsified by: Neuronal viability in dual inhibitor group is not significantly different from or worse than vehicle control (<110% of vehicle), indicating no neuroprotective effect of dual inhibition

Method: Primary cortical neurons from E18 Sprague-Dawley rat embryos cultured 7 days in vitro, subjected to 2 hours OGD followed by drug treatment, viability measured by MTT assay at 48 hours post-OGD

IF N2a neuroblastoma cells or primary neurons are treated with dual calpain/cathepsin B inhibitor before staurosporine-induced apoptosis, THEN cytosolic cathepsin B activity will decrease by >50% and cleaved caspase-3 levels will decrease by >40% compared to vehicle control at 24 hours.

pending conf: 0.50

Expected outcome: Cytosolic cathepsin B activity will be ≤50% of vehicle control; cleaved caspase-3/ß-actin ratio will be ≤60% of vehicle control

Falsified by: Cytosolic cathepsin B activity remains >80% of vehicle control OR cleaved caspase-3 levels remain >80% of vehicle control, indicating failure to block the LMP-apoptosis cascade at either node

Method: N2a cells differentiated with retinoic acid for 48 hours, treated with calpeptin (10 μM) + CA-074me (10 μM) 1 hour before staurosporine (1 μM) induction; cytosolic fraction isolated by subcellular fractionation at 24 hours; cathepsin B activity fluorometric assay (Abcam) and cleaved caspase-3 immunoblot

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

Source Analysis

Why does autophagy inhibition improve neuronal survival when autophagy is typically neuroprotective?

neurodegeneration | 2026-04-15 | archived

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Edit History

Action	Actor	Timestamp	Reason	Changes
update	codex:51	2026-04-26T14:44	Backfill data_support_score with cited empirical sources [task:2ab61458-7bb9-47d	Changes recorded
update	codex:51	2026-04-26T14:44	Backfill data_support_score with cited empirical sources [task:2ab61458-7bb9-47d	Changes recorded

View full edit history (JSON)

Dual Calpain/Cathepsin B Inhibition as Primary Neuroprotective Strategy

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

Dimension Scores

✓ Supporting Evidence 6

✗ Opposing Evidence 4

Mechanistically Novel Hypotheses: Autophagy Paradox in Glucose Deprivation/Reintroduction Neuronal Death

Hypothesis 1: Autophagosome Overload-Induced Lysosomal Membrane Permeabilization (LMP)

Skeptic's Evaluation of Autophagy Paradox Hypotheses

Hypothesis 1: Autophagosome Overload-Induced LMP

Strongest Specific Weakness: Mechanistic Inconsistency with Source Data

Domain Expert Evaluation: Autophagy Paradox Hypotheses

1. Translational Potential Ranking

Highest Translational Priority: Hypothesis 1 (Autophagosome Overload → LMP) combined with calpain pathway

Price History

Clinical Trials (1)

📚 Cited Papers (6)

📅 Citation Freshness Audit

📙 Related Wiki Pages (0)

📓 Linked Notebooks (0)

⚔ Arena Performance

🔄 Related Hypotheses

🧬 Same Target Gene / Disease (30)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

Efficiency Price Signals

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (0 edges)

Source Analysis

Why does autophagy inhibition improve neuronal survival when autophagy is typically neuroprotective?

Community Feedback

Edit History